New data published by the UK Health Security Agency (UKHSA) has revealed that London is potentially at risk of a measles resurgence.
UKHSA modelling suggests that, unless MMR vaccination rates improve, London could see a measles outbreak with tens of thousands of cases.“Those who have never received a measles vaccine (MMR) are at risk,” said UKHSA.MMR is part of the NHS Routine Childhood Immunisation Programme. Parents whose infants missed out, or anyone of any age unvaccinated, are urged to come forward.Susceptibility is particularly high among 19 to 25 year olds, affected by unfounded stories in the early 2000s (‘Wakefield cohorts’) and some may still not be fully vaccinated.As part of continued efforts to protect people against getting measles, the NHS is launching a campaign encouraging people to check their vaccination status, with targeted outreach to groups in London.Data published today by the UK Health Security Agency (UKHSA) shows there has been a steady rise in measles cases this year. It shows, between 1 January and 30 June this year there have been 128 cases of measles, compared to 54 cases in the whole of 2022, with 66 per cent of the cases detected in London although cases have been seen in all regions.The UKHSA assessment finds the risk of a measles epidemic across the UK is considered low. However, with lower current levels of coverage in London, a measles outbreak of between 40,000 and 160,000 cases could occur in the capital.The assessment also concludes that there is a high risk of cases linked to overseas travel leading to outbreaks in specific population groups such as young people and under-vaccinated communities.The risk in London is primarily due to low vaccination rates over several years, further impacted by the COVID-19 pandemic, particularly in some areas and groups where coverage of the first MMR dose at 2 years of age is as low as 69.5%.NHS England has launched a targeted national campaign to encourage uptake of the MMR vaccine, including targeted outreach work in London for those identified as at high risk and communities with the lowest uptake of vaccination.Search
Latest Stories
Start your day right!
Get the latest updates and insights delivered to your inbox
Related News
More For You
NPA calls for end to prescription charge after freeze announcement
Apr 28, 2025
The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.
Patients will continue paying £9.90 to collect their medication from a pharmacy.
The Government today said the move would save patients about £18 million next year while those already exempt from paying prescriptions would continue to be so.
However, England is the only country in the UK that still charges for prescription medicine.
"It is good news for patients and pharmacies that the government has taken the step to freeze the prescription charge today for the first time in three years,” said Nick Kaye, chair of the NPA.
"However, we've long called for the prescription charge to be scrapped, which acts as a barrier to some patients accessing vital medication and this is something we'd urge the government to work towards.
"As pharmacists, we are health care professionals and have no interest in being tax collectors.”
“Today we are freezing prescription charges so that means they won't go over £10 and that is really significant, because very many people have to pay for prescriptions.”
Prime minister Sir Keir Starmer said the freeze to the prescription charge was part of the government’s plans to ease the cost-of-living crisis.
Three-month and annual prescriptions prepayment certificates are also being frozen for the coming year.
Those who already do not have to pay for their prescription – including children, over-60s, pregnant women and people with certain medical conditions – will continue to avoid the costs.
“There's a sort of cost-of-living crisis that is still very challenging for people, so this is an important measure in that,” he said.
“It's not the only measure of course — we are taking steps on school uniforms to limit the cost of school uniforms, we're driving up the minimum wage, we've got breakfast clubs coming on stream, that's something we announced last week, which will save families about £450.
“Each of these, in their incremental way, will ease the pressure that people feel because of the cost-of-living crisis.”
Approximately £600million is generated each year in revenue from prescription charges in England for the delivery of NHS services.
The freeze also comes just weeks after a record £617 million investment was pledged to boost community pharmacies across the country.
“This Government's plan for change will always put working people first and our moves today to freeze prescription charges will put money back into the pockets of millions of patients,” said health and social care secretary Wes Streeting.
“Fixing our NHS will be a long road — but by working closer with our pharmacies we're saving money and shifting care to the community where it's closer to your home.
“We made the difficult but necessary choices at the budget to fund moves like this and change our NHS so it can once again be there for you when you need it.”
Keep ReadingShow less
Most Popular
Don’t Miss Out
Get the latest updates and insights delivered to your inbox.
RPS unveils new training programme to enhance pharmacists’ prescribing skills
Apr 28, 2025
The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.
The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.
Open to RPS members, the programme will begin on 23 June 2025 and run for 18 months.
It will offer practical, ongoing support for pharmacists who are new to prescribing, returning to practice, or looking to expand their scope.
The programme will cover six themes, changing the theme every three months.
Each quarter, participants will explore a new theme through flexible, bite-sized learning formats, including podcasts, blogs, webinars, and e-learning modules available via RPS Learn.
They will also be able to build a personalised prescribing portfolio and track their development using the RPS Competency Framework for Prescribers.
“This new programme is about giving pharmacists the confidence and tools they need to thrive as prescribers,” said Helen Chang, RPS associate director for education.
“With independent prescribing becoming a central part of pharmacy practice, it’s crucial that pharmacists feel supported every step of the way.
"Whether you’re just starting or looking to build on your existing experience, this new training programme offers tailored, ongoing development to help you grow professionally and deliver safe, person-centred care.”
The new programme will build on the RPS’s existing resources for prescribers, including mentoring, Pharmacist Support services and learning content from the Pharmaceutical Journal.
Keep ReadingShow less
Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.
gettyimages
Anti-smoking pill varenicline may help young people quit vaping, new study suggests
Apr 28, 2025
Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.
The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.
The findings were published in JAMA on 23 April 2025.
Researchers noted that electronic cigarettes (vapes) are currently the most commonly used nicotine product among young people, with the highest rates seen in the 18–25 age group.
Alarmingly, the proportion of vapers aged 16 to 25 who have never regularly smoked tobacco is rising.
They warned that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use, alongside direct negative health effects of vapour exposure, such as carcinogen and heavy metal exposure and pulmonary inflammation.
The new study found that varenicline, combined with behavioural counselling, was well-tolerated and promoted vaping cessation compared with placebo in youth with moderate to severe addiction to vaped nicotine.
The randomised clinical trial involved young people aged 16 to 25 who vaped nicotine daily or near daily, did not regularly smoke tobacco, and wanted to reduce or quit vaping.
Conducted in a single US state between June 2022 and May 2024, participants were randomly assigned to one of three groups:
- Varenicline titrated to 1 mg twice daily, plus weekly counselling and text message support;
- A placebo alongside weekly counselling and text message support;
- Enhanced usual care, involving only text-based support.
The results demonstrated that continuous abstinence rates during the final month of treatment were 51% in the varenicline group, compared to 14% in the placebo group. At the six-month follow-up, abstinence rates remained higher among those who received varenicline (28%) compared to placebo (7%).
In the enhanced usual care group, abstinence rates were notably lower, at 6% during treatment and 4% at six months.
Importantly, no drug-related serious adverse events were reported.
“Discovering and delivering effective treatments for nicotine addiction, particularly in youth, is important,” the study authors said.
“Most youth who develop addiction to vaped nicotine have never regularly smoked tobacco and wish to quit vaping, highlighting the importance of these findings that an available pharmacotherapy is effective and well tolerated for vaping cessation in this population.”
Darush Attar-Zadeh, a clinical fellow respiratory pharmacist at North West London Integrated Care Board, emphasised that while vapes can aid smoking cessation, they are not risk-free.
“Currently, we only have the Nicorette mouth spray licensed for vaping cessation,” he told The Pharmaceutical Journal. “
“It would be good to see independent research comparing the latest options available in never smokers and ex-smokers who moved onto vapes,” he added.
Varenicline is a generic version of Champix, which Pfizer withdrew from the market in 2021 due to nitrosamine contamination concerns.
It was made available again for NHS patients in November 2024, after being cleared as safe by the Medicines and Healthcare products Regulatory Agency (MHRA).
Research from University College London suggested that varenicline could help over 85,000 people try to quit smoking each year and prevent up to 9,500 smoking-related deaths over the next five years.
Keep ReadingShow less
Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.
Pic credit: gettyimages
Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA
Apr 26, 2025
The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.
“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.
The reminder follows updates to the product information for short-acting beta 2 agonists (SABAs) — including salbutamol and terbutaline — which are used to relieve sudden asthma symptoms such as chest tightness, wheezing, coughing and breathlessness.
Last year, the MHRA updated UK product information for SABAs, strengthening warnings on the risk of asthma deterioration due to SABA overuse.
The National Institute for Health and Care Excellence (NICE) also published new national asthma guidance (NG245) in November 2024, which no longer recommends prescribing SABA alone for any age group.
Instead, the majority of patients are now advised to use combination inhalers containing both preventer (anti-inflammatory) and reliever medicines, either as Anti-Inflammatory Reliever (AIR) or Maintenance and Reliever Therapy (MART).
“Patients should use their preventer inhaler as prescribed by their doctor, even if their asthma feels under control,” said Dr Alison Cave, Chief Safety Officer at the MHRA.
“Blue inhalers are important for treating symptoms during an asthma attack, but should not be used as the only treatment to manage asthma.”
Patients are advised to speak to a healthcare professional if they need their blue inhaler more than twice a week, as this could indicate their asthma is not well controlled.
If asthma symptoms, such as chest tightness, wheezing, coughing or difficulty breathing, worsen or are not relieved by the blue inhaler, patients are advised to seek urgent medical help.
Patients prescribed a blue inhaler for use during asthma attacks should also be prescribed a separate daily preventer inhaler, the MHRA noted.
Those using a blue inhaler without a dose counter are advised to manually track the doses and ensure they always have access to a spare blue inhaler before the current inhaler runs out or expires.
In addition, the MHRA has issued a Drug Safety Update to healthcare professionals, reminding them of the risks associated with the overuse of blue inhalers.
A December 2024 report from the UK National Child Mortality Database (NCMD) revealed that 87% (47 out of 54) of children who died from asthma had been dispensed three or more SABA inhalers in the year prior to their death.
There is a well-established link across all levels of asthma severity between receiving three or more SABA prescriptions in a year and an increased risk of severe asthma exacerbations.
Keep ReadingShow less
The latest successful cohort includes pharmacists from both England and Scotland.
Pic credit: Getty Images
13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet
Apr 25, 2025
The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.
This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.
The latest successful cohort includes pharmacists from both England and Scotland.
In England, candidates were supported through the nationally funded pathway delivered in partnership with NHS England Workforce, Training and Education, and the Centre for Pharmacy Postgraduate Education (CPPE). Meanwhile, Scottish candidates received support from their employers and NHS Education for Scotland (NES).
These pharmacists have successfully demonstrated their advanced capabilities across five domains:
Person-centred care and collaboration
Professional practice
Leadership and management
Education
Research
Those in England who completed the funded pathway are now eligible to apply for an ‘Advanced’ digital badge from the Centre for Advancing Practice.
In addition, all successful candidates who are RPS members will be able to use the modified membership affix MRPharmS (Advanced) and listed in the RPS directory of core advanced credentialled members.
Susan Roberts, RPS advanced pharmacist assessment panel chair, praised the new cohort’s achievements: “Each has evidenced advanced capabilities across the five curriculum domains and demonstrated how they lead the safe and effective use of medicines across their organisations for patients with highly complex needs.”
“Their success is not only a personal milestone but a powerful endorsement of the value of credentialing for driving professional advancement and assuring excellence in pharmacy practice for individuals, employers, patients and the wider health service.”
“These pharmacists are already making a real difference to patient care, and their achievements support our vision for a structured, supported and advanced career pathway in pharmacy.”
Adepeju E Deekae, one of the newly credentialled pharmacists, reflected on the journey:
“Developing my portfolio gave me the opportunity to reflect on my practice, map existing evidence to domain outcomes and identify gaps in knowledge and practice.”
“With support from expert mentors and collaborators, I was able to draw on years of experience to evidence my competence. It also enabled me to engage with the wider multidisciplinary team and gain support from senior stakeholders, particularly in leadership and management.”
“ The feedback from assessors will help shape my ongoing development towards consultant level.”
Keep ReadingShow less
Load More
© Copyright 2025 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc